Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
accepted:
06
07
2022
pubmed:
23
7
2022
medline:
5
8
2022
entrez:
22
7
2022
Statut:
ppublish
Résumé
Multiple sclerosis treatment made substantial headway during the last two decades with the implementation of therapeutics with new modes of action and routes of application. We are now in the situation that second-generation molecules, approved since 2018, are on the market, characterized by reduced side effects using a more tailored therapeutic approach. Diroximel fumarate is a second-generation fumarate with reduced gastrointestinal side effects. Moreover, several novel, selective, sphingosine-1-phosphate receptor modulators with reduced off-target effects have been developed; namely siponimod, ozanimod, and ponesimod; all oral formulations. B-cell-targeted therapies such as ocrelizumab, given intravenously, and since 2021 ofatumumab, applied subcutaneously, complement the spectrum of novel therapies. The glycoengineered antibody ublituximab is the next anti-CD20 therapy about to be approved. Within the next years, oral inhibitors of Bruton's tyrosine kinase, currently under investigation in several phase III trials, may be licensed for multiple sclerosis. Those developments currently offer an individualized multiple sclerosis therapy, targeting patient needs with substantial effects on relapses, disability progression, and implications for daily life. In this up-to-date review, we provide a holistic overview about novel developments of the therapeutic landscape and upcoming approaches for multiple sclerosis treatment.
Identifiants
pubmed: 35869335
doi: 10.1007/s40263-022-00939-9
pii: 10.1007/s40263-022-00939-9
pmc: PMC9307218
doi:
Substances chimiques
Antigens, CD20
0
Fumarates
0
Sphingosine 1 Phosphate Receptor Modulators
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
803-817Informations de copyright
© 2022. The Author(s).
Références
Faissner S, Gold R. Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. CNS Drugs. 2018;32(3):269–87.
pubmed: 29600441
doi: 10.1007/s40263-018-0488-6
He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307–16.
pubmed: 32199096
doi: 10.1016/S1474-4422(20)30067-3
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175–87.
pubmed: 30644981
pmcid: 6439772
doi: 10.1001/jama.2018.20588
Gold R, Arnold DL, Bar-Or A, Fox RJ, Kappos L, Mokliatchouk O, et al. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results. Mult Scler. 2022;28(5):801–16.
pubmed: 34465252
doi: 10.1177/13524585211037909
Palte MJ, Wehr A, Tawa M, Perkin K, Leigh-Pemberton R, Hanna J, et al. Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study. Adv Ther. 2019;36(11):3154–65.
pubmed: 31538304
pmcid: 6822793
doi: 10.1007/s12325-019-01085-3
Wundes A, Wray S, Gold R, Singer BA, Jasinska E, Ziemssen T, et al. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. Ther Adv Neurol Disord. 2021;14:1756286421993999.
pubmed: 33796143
pmcid: 7985943
doi: 10.1177/1756286421993999
Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler. 2020;26(13):1729–39.
pubmed: 31680631
doi: 10.1177/1352458519881761
Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020;34(2):185–96.
pubmed: 31953790
pmcid: 7018784
doi: 10.1007/s40263-020-00700-0
Wray S, Then Bergh F, Wundes A, Arnold DL, Drulovic J, Jasinska E, et al. Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase 3 EVOLVE-MS-1 Study. Adv Ther. 2022;39(4):1810–31.
pubmed: 35211872
pmcid: 8870078
doi: 10.1007/s12325-022-02068-7
Singer BA, Faissner S, Lyons J, Scaramozza M, Woodward C, Chen H, Branco F, Vosoughi R. Flushing and flushing-related adverse events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis: results from the phase 3 EVOLVE-MS-2 study. Presented at the 37th congress of the European committee for treatment and research in multiple sclerosis; October 13–15, 2021, p. 673.
Lategan TW, Wang L, Sprague TN, Rousseau FS. Pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam™ (monomethyl fumarate) or Tecfidera
pubmed: 33797063
pmcid: 8144082
doi: 10.1007/s40263-021-00799-9
Glaenzel U, Jin Y, Nufer R, Li W, Schroer K, Adam-Stitah S, et al. Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018;46(7):1001–13.
pubmed: 29735753
doi: 10.1124/dmd.117.079574
Pan S, Gray NS, Gao W, Mi Y, Fan Y, Wang X, et al. Discovery of BAF312 (siponimod), a potent and selective S1P receptor modulator. ACS Med Chem Lett. 2013;4(3):333–7.
pubmed: 24900670
pmcid: 4027137
doi: 10.1021/ml300396r
Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035–47.
pubmed: 22646698
pmcid: 3485666
doi: 10.1111/j.1476-5381.2012.02061.x
Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004;279(14):13839–48.
pubmed: 14732717
doi: 10.1074/jbc.M311743200
Mannioui A, Vauzanges Q, Fini JB, Henriet E, Sekizar S, Azoyan L, et al. The Xenopus tadpole: an in vivo model to screen drugs favoring remyelination. Mult Scler. 2018;24(11):1421–32.
pubmed: 28752787
doi: 10.1177/1352458517721355
O’Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1/S1PR5 drug BAF312 (siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflamm. 2016;8(13):31.
doi: 10.1186/s12974-016-0494-x
Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflamm. 2016;13(1):207.
doi: 10.1186/s12974-016-0686-4
Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756–67.
pubmed: 23764350
doi: 10.1016/S1474-4422(13)70102-9
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–73.
pubmed: 29576505
doi: 10.1016/S0140-6736(18)30475-6
Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, et al. Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses. Neurology. 2021;96(3):e376–86.
pubmed: 33328324
doi: 10.1212/WNL.0000000000011275
FDA NEWS RELEASE: FDA approves new oral drug to treat multiple sclerosis. https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-drug-treat-multiple-sclerosis . Accessed 20 June 2022.
European Medicines Agency. Siponimod product information. 22 June 2022. https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_de.pdf . Accessed 14 Jul 2022.
Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016;173(11):1778–92.
pubmed: 26990079
pmcid: 4867749
doi: 10.1111/bph.13476
Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021–33.
pubmed: 31492652
doi: 10.1016/S1474-4422(19)30238-8
Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009–20.
pubmed: 31492651
doi: 10.1016/S1474-4422(19)30239-X
Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, et al. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: post hoc analysis of phase 3 ozanimod trials. Eur J Neurol. 2021;28(11):3722–30.
pubmed: 34292643
pmcid: 9291872
doi: 10.1111/ene.15009
Tran JQ, Hartung JP, Olson AD, Mendzelevski B, Timony GA, Boehm MF, et al. Cardiac safety of ozanimod, a novel sphingosine-1-phosphate receptor modulator: results of a thorough QT/QTc study. Clin Pharmacol Drug Dev. 2018;7(3):263–76.
pubmed: 28783871
doi: 10.1002/cpdd.383
Company B-MS. Zeposia. Prescribing information. Bristol-Myers Squibb; 2021.
Roy R, Alotaibi AA, Freedman MS. Sphingosine 1-phosphate receptor modulators for multiple sclerosis. CNS Drugs. 2021;35(4):385–402.
pubmed: 33797705
doi: 10.1007/s40263-021-00798-w
Olsson T, Boster A, Fernández Ó, Freedman MS, Pozzilli C, Bach D, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014;85(11):1198–208.
pubmed: 24659797
doi: 10.1136/jnnp-2013-307282
Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol. 2021;78(5):558–67.
pubmed: 33779698
doi: 10.1001/jamaneurol.2021.0405
Freedman MS, Pozzilli C, Havrdova EK, Lemle A, Burcklen M, Larbalestier A, et al. Long-term treatment with ponesimod in relapsing-remitting multiple sclerosis: results from randomized phase 2b core and extension studies. Neurology. 2022 Jun 6.
Faissner S, Hoepner R, Lukas C, Chan A, Gold R, Ellrichmann G. Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther Adv Neurol Disord. 2015;8(5):233–8.
pubmed: 26557898
pmcid: 4622113
doi: 10.1177/1756285615594575
Litwin T, Smoliński Ł, Członkowka A. Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod. Neurol Neurochir Pol. 2018;52(1):98–101.
Stamatellos VP, Rigas A, Stamoula E, Lallas A, Papadopoulou A, Papazisis G. S1P receptor modulators in multiple sclerosis: detecting a potential skin cancer safety signal. Mult Scler Relat Disord. 2022;59: 103681.
pubmed: 35168096
doi: 10.1016/j.msard.2022.103681
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–34.
pubmed: 28002679
doi: 10.1056/NEJMoa1601277
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–20.
pubmed: 28002688
doi: 10.1056/NEJMoa1606468
Giovannoni G, Kappos L, de Seze J, Hauser SL, Overell J, Koendgen H, et al. Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. Eur J Neurol. 2022;29(4):1238–42 .
Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2020;19(12):998–1009.
pubmed: 33129442
doi: 10.1016/S1474-4422(20)30342-2
Kappos LM, Hauser X, Julian SL, Manfrini L, Belachew M, Model S, et al. Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the phase III ORATORIO study. Eur J Neurol Supplement. 2018. 4th Congress of the European Academy of Neurology; 16–19 June 2018; Lisbon.
Ng HS, Rosenbult CL, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opin Drug Saf. 2020;19(9):1069–94.
pubmed: 32799563
doi: 10.1080/14740338.2020.1807002
Roche. Ocrelizumab and PML. 2021. wwwocrelizumabinfoglobal. Accessed 15 Jul 2022.
Smets I, Reyes S, Baker D, Giovannoni G. Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment. Mult Scler Relat Disord. 2021;21(50): 102851.
doi: 10.1016/j.msard.2021.102851
Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97(19):e1870–85.
pubmed: 34610987
pmcid: 8601210
doi: 10.1212/WNL.0000000000012753
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012836.
pubmed: 34035836
pmcid: 8072850
Faissner S, Heitmann N, Rohling R et al. Preserved T-cell response in anti-CD20 treated multiple sclerosis patients following SARS-CoV-2 vaccination, 09 December 2021, PREPRINT (Version 1) available at Research Square. https://doi.org/10.21203/rs.3.rs-1109886/v1
Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27(11):1990–2001.
pubmed: 34522051
pmcid: 8604727
doi: 10.1038/s41591-021-01507-2
Masoud S, McAdoo SP, Bedi R, Cairns TD, Lightstone L. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology (Oxford). 2018;57(7):1156–61.
doi: 10.1093/rheumatology/key042
Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;183(1):749–58.
pubmed: 19535640
doi: 10.4049/jimmunol.0900632
Kähäri L, Fair-Mäkelä R, Auvinen K, Rantakari P, Jalkanen S, Ivaska J, et al. Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes. J Clin Invest. 2019;129(8):3086–102.
pubmed: 31232704
pmcid: 6668680
doi: 10.1172/JCI125740
Torres J et al. Distribution and efficacy of Ofatumumab and Ocrelizumab in humanized-CD20 mice following subcutaneous or intravenous administration. Poster presentation. 2019 AAN.
Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–88.
pubmed: 18272891
doi: 10.1056/NEJMoa0706383
Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82(7):573–81.
pubmed: 24453078
doi: 10.1212/WNL.0000000000000125
Kurrasch R, Brown JC, Chu M, Craigen J, Overend P, Patel B, et al. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. J Rheumatol. 2013;40(7):1089–96.
pubmed: 23729801
doi: 10.3899/jrheum.121118
Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2021;4:13524585211044480.
Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90(20):e1805–14.
pubmed: 29695594
pmcid: 5957306
doi: 10.1212/WNL.0000000000005516
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546–57.
pubmed: 32757523
doi: 10.1056/NEJMoa1917246
Flores-Gonzalez RE, Hernandez J, Tornes L, Rammohan K, Delgado S. Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab. Mult Scler Relat Disord. 2021;19(49): 102777.
doi: 10.1016/j.msard.2021.102777
Adamec I, Rogić D, Penz MG, Braun C, Habek M. Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab. J Neuroimmunol. 2022;15(362): 577788.
doi: 10.1016/j.jneuroim.2021.577788
Fox E, Lovett-Racke AE, Gormley M, Liu Y, Petracca M, Cocozza S, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mul Scler. 2021;27(3):420–9.
doi: 10.1177/1352458520918375
de Weers M, Verschuren MC, Kraakman ME, Mensink RG, Schuurman RK, van Dongen JJ, et al. The Bruton’s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol. 1993;23(12):3109–14.
pubmed: 8258324
doi: 10.1002/eji.1830231210
Martin E, Aigrot MS, Grenningloh R, Stankoff B, Lubetzki C, Boschert U, et al. Bruton’s tyrosine kinase inhibition promotes myelin repair. Brain Plast. 2020;5(2):123–33.
pubmed: 33282676
pmcid: 7685672
doi: 10.3233/BPL-200100
Faissner S, Gold R. Progressive multiple sclerosis: latest therapeutic developments and future directions. Ther Adv Neurol Disord. 2019;12:1756286419878323.
pubmed: 31598138
pmcid: 6764045
doi: 10.1177/1756286419878323
Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov. 2019;18(12):905–22.
pubmed: 31399729
doi: 10.1038/s41573-019-0035-2
Estupiñán HY, Berglöf A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9: 630942.
pubmed: 33777941
pmcid: 7991787
doi: 10.3389/fcell.2021.630942
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):729–38.
pubmed: 34418400
doi: 10.1016/S1474-4422(21)00237-4
Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med. 2019;380(25):2406–17.
pubmed: 31075187
doi: 10.1056/NEJMoa1901981